
TSE:ATS
This summary was created by AI, based on 5 opinions in the last 12 months.
ATS Automation Tooling Systems (ATS-T) has garnered attention from experts for its compelling position in the automation sector, particularly in light of current trends like reshoring and labor scarcity. Despite experiencing some volatility, recent earnings reports indicate that the company's revenue has surpassed expectations, although bookings have shown signs of softening. Many analysts see potential for growth, with price targets hovering around $49-$50 and an upside of approximately 10% to 25%. While some concerns were raised regarding short-term growth and recent leadership changes, the overall sentiment remains positive, highlighting sustainable profitability and a strong project pipeline. The consensus reflects a belief that ATS Automation remains a robust investment opportunity for the coming months.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It is sensitive to broad economic growth and is likely why the shares are dragging down. Trading at 16x forward earnings and good growth is expected. Risks are most likely already priced in. Cost pressures and slowdowns are possible, but many companies, including ATA will manage through them. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The stock is up more than 100% in the past year. It has slightly declined but it is more on sell on news right now. EPS estimates beat last quarter. Backlog is nearly $1.5B and sales are climbing 48%. A solid quarter. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Could deliver good growth although it is more in the cyclical business. Business is solid and the stock has hit more investor’s radar. 3 year + timeframe. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Earnings report was overall good. Revenues beat expectations by $20M. Backlog is up 23% to $1.1B and EPS is $0.34. EBITDA margins have increased. Their acquisition of BioDot is going well. Shares are up 4% after the report. Unlock Premium - Try 5i Free